Pfizer‘s final results from the COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday, reported Reuters.
In Latin America, Pfizer’s vaccine has been in trials in Brazil and Argentina. Mexico and Ecuador already have deals to purchase Pfizer’s doses.
Also, according to Reuters, Brazil’s Health Ministry said in a statement on Tuesday that the country would purchase the Pfizer’s COVID-19 vaccine after it is proven safe in clinical trials and registered with the domestic health regulator.
The announcement from Pfizer comes after pharmaceutical firm Moderna on Monday released preliminary data for its vaccine, showing 94.5% effectiveness. As Reuters reported, the better-than-expected results from the two vaccines have raised hopes for an end to a pandemic that has killed more than 1.3 million people and wreaked havoc upon economies and daily life.